Technology | November 19, 2012

Hologic to Showcase Award Winning 3D Mammography and Other Advanced Imaging Technologies at RSNA 2012

Hologic’s best-in-class solutions for breast screening, intervention and treatment, osteoporosis risk assessment and extremity imaging highlight its commitment to putting Patients First

3D mammography (breast tomosynthesis) system

U.S. Food and Drug Administration (FDA) in February 2011 and has been available in countries recognizing the CE mark since 2008. Hologic’s 3D mammography technology is available in 46 states and 29 countries outside the U.S.

Hologic’s 3D mammography system placed first in the digital mammography category in the KLAS 2012 annual survey of healthcare executives and clinicians. 3D mammography was recently selected by AuntMinnie as the “hottest clinical procedure” of the year for the third year in a row. AuntMinnie is the largest and most comprehensive community Web site for medical imaging professionals worldwide. In October, the Cleveland Clinic picked 3D mammography as one of the Top 10 Medical Innovations for 2013 at the Clinic's 10th annual Medical Innovation Summit.

Fifteen of the clinical papers and over 50 of the workshops, seminars, poster sessions and scientific papers to be presented at the conference are on 3D mammography (breast tomosynthesis).  Clinical presentations cover the use of tomosynthesis in screening and diagnostic applications.

Hologic is once again offering RSNA meeting attendees sixteen 75-minute sessions with hands-on experience reading 3D breast tomosynthesis images in combination with conventional and synthesized 2D images. Brief lectures will provide an overview of the technologies prior to the hands-on sessions. Each program will be taught by a leading breast imaging radiologist.  Conference attendees can register to take a workshop through the RSNA meeting web site.

Some of Hologic’s other advances in breast tomosynthesis on display at the conference include its tomosynthesis biopsy option for use with the Affirm™ biopsy guidance system and its C-View™ synthesized 2D image option. The tomosynthesis biopsy option is CE marked and is pending FDA clearance. The C-View Synthesized 2D image option received CE marking in 2011 and received a favorable vote for approval from an FDA Advisory Panel in October 2012. 

For more information: www.hologic.com

Related Content

RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch
Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...